-
In this issue: FDA issues multiple drug safety alerts; ARBs and cancer risk; and FDA actions.
-
Seven patients were identified when DAP-ASBL therapy was used to eradicate persistent MRSA bacteremia. Isolates from 3 patients were available for in vitro study.
-
Pneumocystis jirovecii pneumonia (PCP) is a common opportunistic infection (OI) in AIDS patients. Laboratory diagnosis of this life-threatening infection is based primarily upon identifying P. jirovecii cysts in respiratory secretions, a technique that is variably sensitive and requires adequate patient effort (for induced sputum examination) or an invasive test (bronchoscopy); both are quite operator dependent.
-
-
By 2007, the prevalence of fluoroquinolone resistance among N. gonorrhoeae had become so widespread in the United States that the CDC recommended against use of drugs of that class in the treatment of gonorrhea.
-
The United States Perinatal HIV Surveillance Project tracks HIV-infected pregnant women in care in 15 locations throughout the United States and Puerto Rico.
-
A consortium of 10 pediatric hospitals in Bangladesh, Egypt, Malawi, Pakistan, and Vietnam was assembled by the World Health Organization CSF5 study group with funding from the U.S. Agency for International Development to compare 5 days vs. 10 days of therapy with ceftriaxone.
-
The authors conducted a series of experiments in which HIV-1 transfected 1G5 T cells were exposed to either a series of known long terminal repeat (TLR) ligands (FimH/TLR-4, flagellin/TLR-5, and poly I:C/TLR-3) or STI pathogens (HSV-1, HSV-2, and N. gonorrhoeae).
-
A total of 130 singleton stillbirths from a single institution in Australia, from January 2005 through December 2006, of > 20 weeks gestation with no cause of death and with available formalin-fixed, paraffin-embedded tissues were examined by multiplex PCR for 19 infectious agents, and by immunohistochemistry for human cytomegalovirus (CMV).
-
In this issue: Apixaban could soon join the anticoagulation market; Chinese herbs for flu; chronic medication and discontinuation after hospitalization; and FDA actions.